Author details

Full Name

Massimo Pizzato

Affiliation

ORCID

Career Start Year

1984

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37290944	Trends and symptoms of SARS-CoV-2 infection: a longitudinal study on an Alpine population representative sample.	BMJ Open	2023
36992361	A Conserved Acidic Residue in the C-Terminal Flexible Loop of HIV-1 Nef Contributes to the Activity of SERINC5 and CD4 Downregulation.	Viruses	2023
34637685	Prospective epidemiological, molecular, and genetic characterization of a novel coronavirus disease in the Val Venosta/Vinschgau: the CHRIS COVID-19 study protocol.	Pathog Glob Health	2022
35215902	A Community Study of SARS-CoV-2 Detection by RT-PCR in Saliva: A Reliable and Effective Method.	Viruses	2022
35328442	Host Restriction Factors Modulating HIV Latency and Replication in Macrophages.	International Journal of Molecular Sciences	2022
35196644	SARS-CoV-2 vaccination elicits unconventional IgM specific responses in naÃ¯ve and previously COVID-19-infected individuals.	eBioMedicine	2022
34578326	Doxycycline Inhibition of a Pseudotyped Virus Transduction Does Not Translate to Inhibition of SARS-CoV-2 Infectivity.	Viruses	2021
35602204	Serology study after BTN162b2 vaccination in participants previously infected with SARS-CoV-2 in two different waves versus naÃ¯ve.		2021
33532784	SARS-CoV-2 recruits a haem metabolite to evade antibody immunity.	medRxiv	2021
34056416	Effect of High-Energy Milling on the Dissolution of Anti-HIV Drug Efavirenz in Different Solvents.	ACS Omega	2021
33888467	SARS-CoV-2 can recruit a heme metabolite to evade antibody immunity.	Sci Adv	2021
33350486	Centriolar distal appendages activate the centrosome-PIDDosome-p53 signalling axis via ANKRD26.	EMBO Journal	2021
33173092	Impaired ability of Nef to counteract SERINC5 is associated with reduced plasma viremia in HIV-infected individuals.	Scientific Reports	2020
30566072	The antiviral activity of rodent and lagomorph SERINC3 and SERINC5 is counteracted by known viral antagonists.	Journal of General Virology	2019
31811051	Correction: The host-cell restriction factor SERINC5 restricts HIV-1 infectivity without altering the lipid composition and organization of viral particles.	Journal of Biological Chemistry	2019
29688125	Mechanical activation of Efavirenz: the effects on the dissolution and inhibitory behavior.	Pharmaceutical Development and Technology	2018
30265629	SERINC5 as a New Restriction Factor for Human Immunodeficiency Virus and Murine Leukemia Virus.	Annual Review of Virology	2018
29268082	Localization to detergent-resistant membranes and HIV-1 core entry inhibition correlate with HIV-1 restriction by SERINC5.	Virology	2018
28179429	SERINC5 protein inhibits HIV-1 fusion pore formation by promoting functional inactivation of envelope glycoproteins.	Journal of Biological Chemistry	2017
28659343	The host-cell restriction factor SERINC5 restricts HIV-1 infectivity without altering the lipid composition and organization of viral particles.	Journal of Biological Chemistry	2017
27631701	The Potency of Nef-Mediated SERINC5 Antagonism Correlates with the Prevalence of Primate Lentiviruses in the Wild.	Cell Host Microbe	2016
27803322	S2 from equine infectious anemia virus is an infectivity factor which counteracts the retroviral inhibitors SERINC5 and SERINC3.	Proceedings of the National Academy of Sciences of the United States of America	2016
27681140	The Antagonism of HIV-1 Nef to SERINC5 Particle Infectivity Restriction Involves the Counteraction of Virion-Associated Pools of the Restriction Factor.	Journal of Virology	2016
26416734	HIV-1 Nef promotes infection by excluding SERINC5 from virion incorporation.	Nature	2015
25595806	Retroviral factors promoting infectivity.	Progress in Molecular Biology and Translational Science	2015
25691535	Galanin pathogenic mutations in temporal lobe epilepsy.	Hum Mol Genet	2015
26181333	Lv4 Is a Capsid-Specific Antiviral Activity in Human Blood Cells That Restricts Viruses of the SIVMAC/SIVSM/HIV-2 Lineage Prior to Integration.	PLoS Pathogens	2015
24904546	The activity of Nef on HIV-1 infectivity.	Frontiers in Microbiology	2014
23094081	The carboxyl-terminus of human immunodeficiency virus type 2 circulating recombinant form 01_AB capsid protein affects sensitivity to human TRIM5Î±.	PLoS ONE	2012
23227216	Quantification of reverse transcriptase activity by real-time PCR as a fast and accurate method for titration of HIV, lenti- and retroviral vectors.	PLoS ONE	2012
22194689	Nef decreases HIV-1 sensitivity to neutralizing antibodies that target the membrane-proximal external region of TMgp41.	PLoS Pathogens	2011
21512573	TRIM5 is an innate immune sensor for the retrovirus capsid lattice.	Nature	2011
20439730	MLV glycosylated-Gag is an infectivity factor that rescues Nef-deficient HIV-1.	Proceedings of the National Academy of Sciences of the United States of America	2010
20181694	Cyclosporine blocks incorporation of HIV-1 envelope glycoprotein into virions.	Journal of Virology	2010
19022294	A one-step SYBR Green I-based product-enhanced reverse transcriptase assay for the quantitation of retroviruses in cell culture supernatants.	Journal of Virological Methods	2009
18715908	Nef can enhance the infectivity of receptor-pseudotyped human immunodeficiency virus type 1 particles.	Journal of Virology	2008
18842727	Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency virus research.	Journal of Virology	2008
17412836	Dynamin 2 is required for the enhancement of HIV-1 infectivity by Nef.	Proceedings of the National Academy of Sciences of the United States of America	2007
15681054	Insertion of targeting domains into the envelope glycoprotein of Moloney murine leukemia virus (MoMLV)-based vectors modulates the route of mCAT-1-mediated viral entry.	Virus Research	2005
12706092	Molecular cloning, complete sequence, and biological characterization of a xenotropic murine leukemia virus constitutively released from the human B-lymphoblastoid cell line DG-75.	Virology	2003
12050401	Nef enhances human immunodeficiency virus type 1 infectivity in the absence of matrix.	Journal of Virology	2002
12072492	Heparin binds to murine leukemia virus and inhibits Env-independent attachment and infection.	Journal of Virology	2002
11420637	Development of a suspension packaging cell line for production of high titre, serum-resistant murine leukemia virus vectors.	Gene Therapy	2001
11526456	Evidence for nonspecific adsorption of targeted retrovirus vector particles to cells.	Gene Therapy	2001
10810612	Retrovirus vectors.	Advances in Experimental Medicine and Biology	2000
21390827	Gene Therapy of Glioblastoma Multiforme with a Bicistronic Retroviral Vector Expressing Human IL-2 and HSV-tK.	Methods in molecular medicine	2000
10815029	Progress with retroviral gene vectors.	Reviews in Medical Virology	2000
10360799	Herpes simplex virus chronically infected human T lymphocytes are susceptible to HIV-1 superinfection and support HIV-1 pseudotyping.	Journal of acquired immune deficiency syndromes (1999)	1999
10435083	Gene therapy of glioblastoma multiforme via combined expression of suicide and cytokine genes: a pilot study in humans.	Gene Therapy	1999
10482613	Initial binding of murine leukemia virus particles to cells does not require specific Env-receptor interaction.	Journal of Virology	1999